Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
42 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.
Sponsor: Alliance for Clinical Trials in Oncology
You may qualify if…
- ✓ • Histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features following complete resection of the primary tumor (radical or partial nephrectomy)
- ✓ Note: Patients with microscopically positive soft tissue or vascular margins without gross residual disease are permitted
- ✓ Intermediate-high risk RCC:
- ✓ pT2 grade 4 or sarcomatoid features, N0M0
- ✓ pT3 any grade N0, M0
- ✓ High-risk RCC
- ✓ pT4, any grade, N0, M0
- ✓ pT, any stage., any grade, N+, M0
Where it's recruiting
Phoenix · Tucson
Jonesboro · Little Rock
Auburn · Beverly Hills · Duarte · Irvine …
Aurora · Colorado Springs · Denver · Fort Collins …
Avon · Bridgeport · Derby · Fairfield …
Millville · Newark · Rehoboth Beach
Washington D.C.
Gainesville · Miami
Atlanta · Johns Creek
Boise · Coeur d'Alene · Fruitland · Meridian …
Aurora · Barrington · Bloomington · Canton …
Avon · Carmel · Indianapolis
Source: ClinicalTrials.gov · NCT06661720 · last updated 2026-11-03